Is it Time to Dump NGM Biopharmaceuticals Inc (NGM) Stock After it Is Up 15.24% in a Week?

Tuesday, October 03, 2023 02:20 PM | InvestorsObserver Analysts

Mentioned in this article

Is it Time to Dump NGM Biopharmaceuticals Inc (NGM) Stock After it Is Up 15.24% in a Week?

Overall market sentiment has been high on NGM Biopharmaceuticals Inc (NGM) stock lately. NGM receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

NGM Biopharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NGM!

See Full NGM Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With NGM Stock Today?

NGM Biopharmaceuticals Inc (NGM) stock is up 4.31% while the S&P 500 is lower by -1.59% as of 2:19 PM on Tuesday, Oct 3. NGM is higher by $0.05 from the previous closing price of $1.16 on volume of 781,587 shares. Over the past year the S&P 500 is up 14.73% while NGM is lower by -90.45%. NGM lost -$2.08 per share in the over the last 12 months.

More About NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease. Click Here to get the full Stock Report for NGM Biopharmaceuticals Inc stock.